id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-271855-k8zlptas	Davis, Corey S.	Opioid Policy Changes During the COVID-19 Pandemic - and Beyond	2020-05-20		.txt	text/plain	1586	82	51	In an attempt to reduce preventable harm to individuals with opioid use disorder (OUD), federal, state, and local governments have temporarily modified law and policy to increase access to OUD treatment and divert some individuals at high risk away from the correctional system. In this Commentary, we briefly describe how people with OUD are at increased risk for COVID-19, discuss existing policy barriers to evidence-based prevention and treatment for individuals with OUD, explain the temporary rollbacks of those barriers, and argue that these changes should be made permanent. 3 Opioid agonist medications for OUD, methadone and buprenorphine, reduce all-cause mortality by as much as fifty percent and are associated with positive changes in a number of other outcomes including reductions in overdose, resumed use, and HIV infections. 5 Finally, the provision of sterile syringes dramatically reduces the risk of bloodborne disease transmission related to sharing syringes for intravenous opioid use, and syringe services programs effectively link individuals with OUD to evidence-based treatment.	./cache/cord-271855-k8zlptas.txt	./txt/cord-271855-k8zlptas.txt